| 000 | 01393nam a2200313 a 4500 | ||
|---|---|---|---|
| 005 | 20250918192343.0 | ||
| 008 | 130730s2012 waua 001 0 eng | ||
| 020 |
_a9780309218139 (pbk.) _cRM165.63 |
||
| 039 | 9 |
_a201310101021 _bzaleha _c201310041119 _dzaleha _c201310021204 _dbalqis _y07-30-2013 _zdiyana |
|
| 040 | _dUKM | ||
| 090 | _aQV771.E841 2012 9HUKM | ||
| 090 |
_aQV771 _b.E841 2012 9HUKM |
||
| 245 | 0 | 0 |
_aEthical and scientific issues in studying the safety of approved drugs / _cCommittee on Ethical and Scientific Issues in Studying the Safety of Approved Drugs, Board on Population Health and Public Health Practice, Institute of Medicine of the National Academies. |
| 260 |
_aWashington, D. C. : _bNational Academies Press, _c2012. |
||
| 300 |
_axvi, 275 p. ; _c23 cm. |
||
| 650 | 2 |
_aDrug Evaluation _xethics. |
|
| 650 | 2 |
_aClinical Trials as Topic _xethics. |
|
| 650 | 2 | _aDrug Approval. | |
| 650 | 2 |
_aProduct Surveillance, Postmarketing _xmethods. |
|
| 651 | 2 | _aUnited States. | |
| 710 | 2 |
_aInstitute of Medicine (U.S.). _bCommittee on Ethical and Scientific Issues in Studying the Safety of Approved Drugs. |
|
| 907 |
_a.b15691044 _b2019-11-12 _c2019-11-12 |
||
| 942 |
_c01 _n0 _kQV771.E841 2012 9HUKM |
||
| 914 | _avtls003535994 | ||
| 990 | _adiyana/za | ||
| 991 | _aJabatan Farmasi, PPUKM | ||
| 998 |
_ah _b2013-04-07 _cm _da _feng _gwau _y0 _z.b15691044 |
||
| 999 |
_c551724 _d551724 |
||